Covx Technology Ireland, Ltd.

Sirius Therapeutics, Inc.

Covx Technologies Ireland Limited

Tallac Therapeutics, Inc.

Tollnine, Inc.

Dingguo Liu

Curt William Bradshaw

Bin Liu

Venkata Ramana Doppalapudi

Sukumar Sakamuri

Abhijit Suresh Bhat

Laxman Eltepu

Jing-Yu Lai

Gang Chen

Yanwen Fu

Joel Desharnais

Bryan R Meade

Son Lam

Ayman Kabakibi

Giuseppe Dello Iacono

Edward Hyungsuk Ha

Bryan Douglas Oates

Joseph Stock

Curt W Bradshaw

Jing Yu Lai

Immunomodulating polynucleotides are disclosed. The immunomodulating polynucleotides may contain 5-modified uridine, 5-modified cytidine, a total of from 6 to 16 nucleotides, and/or one or more abasic spacers and/or internucleoside phosphotriesters. Also disclosed are conjugates containing a targeting moiety and one or more immunomodulating polynucleotides. The immunomodulating polynucleotides and conjugates may further contain one or more auxiliary moieties. Also disclosed are compositions containing the immunomodulating polynucleotides or the conjugates containing one or more stereochemically enriched internucleoside phosphorothioates. Further disclosed are pharmaceutical compositions containing the immunomodulating polynucleotides or the conjugates and methods of their use.

Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use

Disclosed are P-stereogenic groups that may be used in the synthesis of compounds including stereochemically enriched P-stereogenic phosphorothioates. P-stereogenic groups may be provided in nucleoside phosphoramidites including a sugar bonded to a nucleobase and to a stereochemically enriched phosphoramidite as well as methods of their use and methods of making them.

Chiral phosphoramidite auxiliaries and methods of their use

Disclosed are chiral phosphoramidite auxiliary compositions for diastereoselective synthesis of stereochemically enriched oligonucleotides, and nucleoside phosphoramidite compounds comprising the same. Exemplary structures of the chiral phosphoramidite auxiliary compositions include Formulas (IA) and (IB). 

The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules.

Anti-angiogenic compounds

The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody.

Methods of treating a disease or condition associated with abnormal angiogenesis

The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders associated with abnormal angiogenesis.

The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.

Growing community of inventors

San Diego, CA, United States of America

Dingguo Liu